Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueShares Outstanding (Weighted Average)
Others
Ratios

Genoil (GNOLF) EBITDA (2020 - 2025)

Historic EBITDA for Genoil (GNOLF) over the last 7 years, with Q3 2025 value amounting to -$147005.0.

  • Genoil's EBITDA fell 561.69% to -$147005.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year decrease of 2719.88%. This contributed to the annual value of -$2.0 million for FY2024, which is 4504.97% up from last year.
  • Genoil's EBITDA amounted to -$147005.0 in Q3 2025, which was down 561.69% from -$213951.0 recorded in Q2 2025.
  • In the past 5 years, Genoil's EBITDA registered a high of -$104359.0 during Q4 2021, and its lowest value of -$2.2 million during Q1 2023.
  • Over the past 5 years, Genoil's median EBITDA value was -$169551.0 (recorded in 2022), while the average stood at -$455711.5.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 71164.0% in 2023, then surged by 9375.61% in 2024.
  • Quarter analysis of 5 years shows Genoil's EBITDA stood at -$104359.0 in 2021, then tumbled by 36.84% to -$142801.0 in 2022, then tumbled by 711.64% to -$1.2 million in 2023, then tumbled by 33.71% to -$1.5 million in 2024, then skyrocketed by 90.51% to -$147005.0 in 2025.
  • Its last three reported values are -$147005.0 in Q3 2025, -$213951.0 for Q2 2025, and -$147506.0 during Q1 2025.